Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
Both companies have upped their bids, but Novo Nordisk comes armed with an extra $1.9bn.
Therapy Area
AI breakthrough promises earlier prostate cancer diagnosis
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
Health Canada grants NOC for AstraZeneca’s breast cancer therapy
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
